Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GE Healthcare Life Sciences Launches Xuri™ Technology Family

Published: Wednesday, November 13, 2013
Last Updated: Wednesday, November 13, 2013
Bookmark and Share
First product introduced - Xuri Cell Expansion System W25 for the clinical manufacture of cellular immunotherapies.

GE Healthcare Life Sciences has launched Xuri™, a new technology family designed specifically to support and advance the field of cell therapy.

The new technology family, in which the first product is the Xuri Cell Expansion System W25 for the manufacture of cellular immunotherapies in a clinical setting, will combine GE Healthcare’s capabilities in cellular science with the company’s expertise in the development of advanced tools for the manufacture of biopharmaceuticals.

Cell therapy and regenerative medicine, the use of cells to replace damaged tissue or to treat disease, shows great promise for treating many life-threatening and life-limiting illnesses such as cancer, heart disease, Parkinson’s and age-related macular degeneration.

The widespread adoption of these therapies will require the development of robust, scalable manufacturing tools and workflows to generate sufficient, high quality cells for infusion into patients.

With an estimated 2,500 on-going cell therapy and regenerative medicine clinical trials worldwide, many research groups are now looking at how to move from small-scale expansion of cells to a cost-effective, industrialized process.

GE Healthcare’s new Xuri Cell Expansion System W25 is a functionally closed, automated system, specifically designed to be suitable for the requirements of scaling-out cell therapies in a clinical setting.

The system is equipped with dedicated software applications to make it suitable for a regulated manufacturing environment and has been validated for T-cell growth.

The Xuri W25 builds on the GE Healthcare’s WAVE Bioreactor™ technology which is widely used in the development and manufacture of biopharmaceuticals globally.

Eric Roman, General Manager of Research & Applied Markets, GE Healthcare Life Sciences, commented, “Through our scale and innovation, we are committed to addressing the significant challenges that remain in moving from highly promising experimental cell therapies to widely available and affordable treatments. We have an extensive research program, working with leaders in the field such as the Karolinska University Hospital, to develop tailored technologies and workflows. The focus of our Xuri technology family is to enable the safe, reliable and efficient progress of cell therapies from clinical development to commercialization.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare Life Sciences Completes Acquisition of Xcellerex, Inc.
Acquisition expands GE Healthcare’s offering of technologies and services for the manufacture of recombinant proteins, antibodies and vaccines.
Tuesday, May 15, 2012
Scientific News
Shedding Light on HIV Vaccine Design
Broadly speaking - Mathematical modelling of host-pathogen coevolution sheds light on HIV vaccine design.
Progress In Vaccination Against Vespid Venom
Researchers at the Helmholtz Zentrum München and the Technical University Munich have presented a method which facilitates a personalised procedure for wasp allergy sufferers.
New Drug Target for Inflammatory Disorders
Penn study finds enigmatic molecules maintain equilibrium between fighting infection and inflammatory havoc.
Oxygen Can Impair Cancer Immunotherapy
Researchers have identified a mechanism within the lungs where anticancer immune resposnse is inhibited.
LncRNAs Maintain Immune Health
Long non-coding RNAs are key controllers for maintaining immune health when fighting infection or preventing inflammatory disorders.
Researchers Identify Influenza Fighting Molecule
St. Jude scientists have identified the molecule that recognizes influenza virus cells and triggers their death to fight the infection.
Breast Milk Sugar May Protect Babies Against Deadly Infection
Researchers from Imperial College London find that a sugar found in some women’s breast milk may protect babies against Group B streptococcus.
New Method of Cancer Immunotherapy
Stanford chemists have dicovered a new form of cancer immunotherapy using sugar presence manipulation.
Immune Breakthrough: Unscratching Poison Ivy’s Rash
Researchers from Monash University have discovered the molecular cause of poison ivy rash.
Alien-Like Reproduction of Single-Celled Fungi
Biologists have directly observed how microspridia, a single-celled fungi, replicate and spread.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!